PRESS-RELEASE ·Filed Oct 13, 2026
Press release · Offering
Actionable Insight • Neutral
Monitor TRexBio's pipeline progress and cash runway updates in upcoming quarterly filings; the IPO provides funding for clinical development but the company remains pre-revenue with no approved products.
Latest settled — T+5d ⚠ clustered
TRXB ▲ +12.89% at T+5d
NEUTRAL call +12.89% · α vs SPY +12.44% · entry $13.50 → $15.24
T+1d
+4.89%
call +4.89% · α +4.60%
$14.16
settled 13d ago
T+5d
+12.89%
call +12.89% · α +12.44%
$15.24
settled 7d ago
T+20d
Pending
in 14d
T+60d
Pending
in 2mo
Price Chart
Loading chart...
Executive Summary
TRex Bio, Inc. closed its initial public offering of 8,333,334 shares at $14.00 per share, raising approximately $116.7 million in gross proceeds. The IPO provides the clinical-stage biotech with capital to advance its tissue Treg immunoregulatory pipeline.
Key Financial Metrics
Deal Value
$116.7M
Key Facts
- IPO of 8,333,334 shares priced at $14.00 per share
- Aggregate gross proceeds of approximately $116.7 million
- All shares sold by TRexBio (primary offering)
- Stock listed on Nasdaq Global Select Market under ticker TRXB
- Lead book-running managers: J.P. Morgan, Evercore ISI, Cantor, Stifel; book-running manager: Wedbush PacGrow
- Registration statement (File No. 333-299018) effective October 8, 2026
Financial Impact
Gross proceeds of $116.7 million from IPO
cashdilution
Risk Factors
- Clinical-stage biotech with no approved products or revenue
- Dilution from 8.3 million new shares
- Pipeline execution risk for Treg-based immunoregulatory therapies
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3380200 |
22 reports for TRXB
100% Hit rate @ T+1 Went positive at some point 3 of 3 best @ T+1▲ +5.64%
Filters
Rows
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 16, 2026 10d ago | SC 13G | $14.80 $14.44 | ▼ −2.43% | ▼ −2.77% | $14.00 (−5.41%) |
Oct 16, 2026 10d ago | SC 13D | $14.80 $14.44 | ▼ −2.43% | ▼ −2.77% | $14.00 (−5.41%) |
Oct 16, 2026 10d ago | SC 13D | $14.01 $14.80 | ▲ +5.64% | ▲ +5.22% | $14.00 (−0.07%) |
Oct 15, 2026 11d ago | Insider Cluster | $14.01 $14.80 | ▲ +5.64% | ▲ +5.22% | $14.00 (−0.07%) |
Oct 15, 2026 11d ago | SC 13G | $14.16 $14.01 | ▼ −1.06% | ▲ +0.05% | $14.00 (−1.13%) |
Oct 13, 2026 13d ago | Press Release | $13.50 $14.16 | ▲ +4.89% | ▲ +4.60% | $14.00 (+3.70%) |
Oct 9, 2026 17d ago | 424B4 | $14.03 $13.60 | ▼ −3.06% | ▼ −3.05% | $14.00 (−0.21%) |
Oct 9, 2026 18d ago | EFFECT | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $14.00 (0.00%) |
Oct 8, 2026 18d ago | 3 | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $14.00 (0.00%) |
Oct 8, 2026 18d ago | 3 | $14.00 $14.03 | ▲ +0.21% | ▲ +0.27% | $14.00 (0.00%) |
Showing 10 of 22
US Market Status
Market Open — Closes in 6h 17m
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers